Virios Therapeutics, Inc. (VIRI) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Vireos Therapeutics Incorporated first quarter 2024 earnings call. At this time, all participants have been placed on a listen-only mode. Please be advised that today's call is being recorded at the company's request. At this time, I'd like to turn the call over to Angela Walsh, Senior Vice President of Finance and Treasurer for Vireos Therapeutics. Please proceed, Angela. Good morning, everyone, and thank you for joining us on today's conference call. We are pleased to be with you today to discuss various therapeutics first quarter financial results and to provide a corporate update. Please note that our financial results press release is now available on our website. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involved risks and uncertainties that can cause actual results to differ materially from the information expressed or implied by these forward-looking statements. For more information regarding such risks and uncertainties, please see the risk factors outlined in the company's filings with the SEC. Any forward-looking statements are made only as of today and we disclaim any obligation to update these four Lincoln Statements other than as required by law. Please see the four Lincoln Statements section in our financial results press release issued this morning for more information. Now, it is my pleasure to turn the call over to our CEO, Greg Duncan. Thank you very much, Angela. The team and I are excited to convey a few key progress highlights from the first three months of this year as the first part of today's update. Let's start with the ongoing, investiga...